- OraSure Technologies (NASDAQ:OSUR +25.3%) Q4 results ($M): Revenues: 35.5 (+9.6%); Infectious Disease Testing: 13.7 (-6.0%); Molecular Collection Systems: 8.6 (+10.2%).
- Net Income: 7.2 (+55.9%); EPS: 0.13 (+62.5%); CF Ops (full year): 22.8 (+44.5%).
- "Our fourth quarter financial results exceeded expectations on the top and bottom lines,” said Douglas A. Michels, President and CEO of OraSure Technologies. “A major contributor to growth during both the quarter and full-year period was our international business. Expanding international sales of our HIV self-test and HCV product is a critical component of OraSure’s global growth strategy.”
-
Q1 Guidance: Revenues: $31.0M - 31.5M; EPS: $0.17 - 0.18. Guidance reflects absence of revenues of the now-terminated co-promotion agreement with AbbVie and lower gross margins from international sales.